Michael Ryskin
Stock Analyst at B of A Securities
(1.59)
# 2,234
Out of 4,412 analysts
28
Total ratings
42.86%
Success rate
-7.54%
Average return
Main Sectors:
11 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXAI Exscientia | Downgrades: Neutral | $11 → $9 | $4.03 | +123.33% | 2 | Jan 5, 2024 | |
| MRVI Maravai LifeSciences Holdings | Upgrades: Buy | $10 → $8 | $7.70 | +3.90% | 2 | Dec 12, 2023 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $16.57 | +44.84% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $23.94 | +0.25% | 2 | Jul 31, 2023 | |
| ALGN Align Technology | Maintains: Underperform | $190 → $225 | $309.02 | -27.19% | 5 | Apr 27, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $158.42 | +13.62% | 6 | Nov 4, 2022 | |
| OMIC Singular Genomics Systems | Downgrades: Underperform | $3 | $0.40 | +642.21% | 3 | Aug 10, 2022 | |
| IDXX IDEXX Laboratories | Downgrades: Neutral | $550 → $470 | $499.30 | -5.87% | 1 | May 5, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $8.12 | - | 1 | Apr 18, 2022 | |
| SDGR Schrödinger | Downgrades: Neutral | n/a | $23.97 | - | 2 | Nov 11, 2021 | |
| ABSI Absci | Downgrades: Underperform | n/a | $4.58 | - | 2 | Nov 10, 2021 |
Exscientia
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $9
Current: $4.03
Upside: +123.33%
Maravai LifeSciences Holdings
Dec 12, 2023
Upgrades: Buy
Price Target: $10 → $8
Current: $7.70
Upside: +3.90%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $16.57
Upside: +44.84%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $23.94
Upside: +0.25%
Align Technology
Apr 27, 2023
Maintains: Underperform
Price Target: $190 → $225
Current: $309.02
Upside: -27.19%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $158.42
Upside: +13.62%
Singular Genomics Systems
Aug 10, 2022
Downgrades: Underperform
Price Target: $3
Current: $0.40
Upside: +642.21%
IDEXX Laboratories
May 5, 2022
Downgrades: Neutral
Price Target: $550 → $470
Current: $499.30
Upside: -5.87%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.12
Upside: -
Schrödinger
Nov 11, 2021
Downgrades: Neutral
Price Target: n/a
Current: $23.97
Upside: -
Absci
Nov 10, 2021
Downgrades: Underperform
Price Target: n/a
Current: $4.58
Upside: -